Full text is available at the source.
Abstract
New pharmacologic options have rapidly expanded over the past decade for treating cardiovascular-kidney-metabolic syndrome.
- Several interconnected conditions, including cardiovascular disease and type 2 diabetes, are associated with cardiovascular-kidney-metabolic (CKM) syndrome.
- Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists show strong evidence for cardiovascular and kidney protective benefits in CKM conditions.
- Real-world use of emerging therapies for CKM syndrome is becoming increasingly complex.
- The review will explore the efficacy of these therapies, highlighting their distinct and complementary mechanisms.
Simplified